AMGN: Takeaways from Our Trip to Thousand Oaks and Meetings with AMGN Management (CFO and EVP R&D)

Research evidence excerpt

AMGN: Takeaways from Our Trip to Thousand Oaks and Meetings with AMGN Management (CFO and EVP R&D)

BIOTECHNOLOGY

AMGEN INC. June 16, 2026

its earlier-stage pipeline, where the probability of success is admittedly lower but where

Amgen's scientific depth allows it to selectively identify higher-quality assets. The company

indicated it will continue to focus the vast majority of its BD activity on its four core therapeutic

areas (General Medicine, Inflammation, Oncology, and Rare Disease), while for external

innovation they generally prioritize first-in-class targets across its therapeutic areas of

interest, with more new target flow currently in Rare Disease, Inflammation, and Metabolic,

and less in Oncology and Cardiology. On modalities, Amgen remains anchored in complex

biotherapeutics (a stated strength), small molecules for traditionally difficult targets, and

siRNAs (e.g., olpasiran). Beyond the four core therapeutic areas, Dr. Bradner called out cell

therapies, gene therapies, neuroscience, heme, and women's health as adjacent spaces

he follows closely and where Amgen could potentially expand over time, though none are

areas of significant current investment focus.

• Constructive ADA Engagement on Lipid Management and MariTide Positioning,

With Manufacturing Reinforced as a Key Competitive Moat: Dr. Bradner characterized

the recent medical meetings as an exciting stretch for Amgen, with ADA in particular

drawing significant engagement despite no new clinical data from the MariTide program. The

Repatha VESALIUS-CV subgroup analysis in high-risk diabetes patients was particularly

well received by the physician community, reinforcing the importance of lipid management

as a frequently underappreciated lever in the improvement of the overall health of these

patients.